Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
Open Access
- 4 April 2017
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 117 (1) , 54-62
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis CMedicine, 2015
- Natural history of hepatitis CJournal of Hepatology, 2014
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community‐based StudyThe Kaohsiung Journal of Medical Sciences, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis COncology, 2007
- A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapyHepatology, 2006
- Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in TaiwanJournal of Medical Virology, 2001